Daewoong Pharmaceutical Indonesia

Daewoong Launches New Dyslipidemia Treatment… ‘Lower LDL-C, Lower and Earlier’ with Combination Therapy

Writer

Manager

November 30, 2025

- Introduction of Indonesia’s first 10/5mg Ezetimibe/Rosuvastatin combination tablet, expanding treatment options from low- to very-high-risk dyslipidemia patients

- “The lower the LDL-C, the better for cardiovascular prevention”… Dual-mechanism combination therapy aligned with ESC(European Society of Cardiology) guidelines gains attention

- Korean and Indonesian cardiology leaders emphasize early combination therapy over high-dose statin monotherapy for high-risk patients

‍

(Jakarta, Indonesia — November 29, 2025)

Daewoong Pharmaceutical Indonesia (hereafter “Daewoong”) announced on the 29^th that it has officially launched its dyslipidemia treatment, a fixed-dose combination of Ezetimibe and Rosuvastatin, in Indonesia.

‍

Daewoong’s dyslipidemia treatment is based on the dual mechanism of Rosuvastatin (inhibiting cholesterol synthesis in the liver) and Ezetimibe (inhibiting cholesterol absorption in the small intestine), and has demonstrated strong LDL-C (low-density lipoprotein cholesterol) lowering effects even at low doses compared to monotherapy. Notably, Daewoong is introducing three dosage strengths of Ezetimibe/Rosuvastatin (10/5mg 10/5mg, 10/10mg, and 10/20mg) offering more precise and personalized prescriptions according to each patient’s cardiovascular risk level.

‍

Daewoong held the launch symposium at the JW Marriott Hotel in Jakarta in collaboration with the Indonesian Heart Association (PERKI). More than 170 local cardiologists attended, including dr. Ade Meidian Ambari, SpJP(K), PhD, (President of the Indonesian Heart Association), Prof. Kang Seok Min, MD., Ph.D. (President of the Korean Society of Cardiology, Severance Hospital), and Prof. Won Ho Youn, MD., Ph.D. (Professor, Chung-Ang University Hospital). The symposium, under the theme “Future Perspectives on Dual-Pathway Strategies in Cardiovascular Risk Reduction,” shared recent insights on combination therapy approaches.

From right to left: Mr. Baik In Hyun, Director of Daewoong Pharmaceutical Indonesia; Dr. Ade Meidian Ambari, M.D., Ph.D., FIHA, FAsCC, FJCS, President of the Indonesian Heart Association (PERKI); Prof. Seok-Min Kang, M.D., Ph.D., President of the Korean Society of Cardiology; and Prof. Won Ho Youn, M.D., Ph.D., Professor of Cardiology and dyslipidemia expert from Korea, following a media Q&A session during the launch event of Indonesia’s latest dyslipidemia therapy, a fixed-dose combination of Ezetimibe and Rosuvastatin, hosted by Daewoong Pharmaceutical Indonesia on 29 November 2025.

‍

Baik In Hyun, Head of Indonesia Business Division at Daewoong Pharmaceutical and Director of Daewoong Pharmaceutical Indonesia, stated in his opening remarks, “This product launch demonstrates our commitment to improving patients’ quality of life by providing scientifically proven treatment options in collaboration with local healthcare professionals,” and added, “Going forward, we aim to expand our portfolio of innovative treatments for diabetes, hypertension, and heart failure, becoming a trusted healthcare partner for the Indonesian people through joint research with PERKI and medical experts from both countries.”

Mr. Baik In Hyun, Director of Daewoong Pharmaceutical Indonesia, delivered the opening remarks at the launch event of Indonesia’s first 10/5 mg Ezetimibe/Rosuvastatin combination tablet, held in Jakarta on 29 November 2025

‍

The importance of early and intensive LDL-C management for cardiovascular prevention emerged as a major discussion point during the symposium.

‍

dr. Ade Meidian Ambari, SpJP(K), Ph.D, President of the Indonesian Heart Association, stated, “Over 80% of coronary artery disease patients in Indonesia still fail to reach the LDL-C goal of 70mg/dL, and, only 8.5% achieve the very-high-risk target of 55mg/dL,” and added, “I believe that the combination therapy strategies shared in this symposium will help elevate the standard of cardiovascular care in Indonesia.” He further emphasized, “The latest ESC(European Society of Cardiology) guidelines stress the importance of ‘The lower, the earlier, the better,’ indicating that beyond simply meeting numerical targets, lowering LDL-C as much as possible—especially through early combination therapy—is critical for effective prevention.”

Dr. Ade Meidian Ambari, M.D., Ph.D., FIHA, FAsCC, FJCS, President of the Indonesian Heart Association (PERKI), highlighted that many patients with coronary heart disease in Indonesia have yet to achieve their LDL-C targets, during the launch event of the latest dyslipidemia therapy, a fixed-dose combination of Ezetimibe and Rosuvastatin, hosted by Daewoong Pharmaceutical Indonesia in Jakarta on 29 November 2025.

‍

Korean experts highlighted the effectiveness of combination therapy based on clinical data. Prof. Won Ho Youn, MD., Ph.D from Chung-Ang University Hospital presented findings under the title “Dual Pathway LDL-C Lowering: Global Evidence and Real-World Experience with Ezetimibe + Rosuvastatin,” stating, “Combination therapy that simultaneously inhibits cholesterol absorption and synthesis is an important strategy for achieving LDL-C targets set by global guidelines and improves long-term treatment adherence.” He added, “According to the ACTE study (AJC, 2011) and RACING study (Lancet, 2022), combination therapy showed superior LDL-C lowering effects and lower side effect burden compared to high-dose statin monotherapy.”

Prof. Won Ho Youn, M.D., Ph.D., a professor of cardiology and a dyslipidemia expert from Korea, explained that combination therapy, which simultaneously inhibits both cholesterol absorption and production, is a key strategy for achieving LDL-C targets in accordance with global guidelines, while also improving long-term treatment adherence, during the launch event of the latest dyslipidemia therapy, a fixed-dose combination of Ezetimibe and Rosuvastatin, hosted by Daewoong Pharmaceutical Indonesia in Jakarta on 29 November 2025.

‍

Prof. Kang Seok Min, MD., Ph.D, President of the Korean Society of Cardiology, further stated, “In Korea, the prescription rate for combination therapy with Ezetimibe increased from 4.5% in 2016 to 22.5% in 2020, and LDL-C target achievement rates improved from 41.4% to 62.5% over the same period,” emphasizing that “for high-risk patients, initiating combination therapy without delay is the key for achieving better outcomes.”

Prof. Kang Seok Min, M.D., Ph.D., President of the Korean Society of Cardiology, highlighted that, for high-risk patients, initiating combination therapy without delay is key to achieving better clinical outcomes, during the launch event of the latest dyslipidemia therapy, a fixed-dose combination of Ezetimibe and Rosuvastatin, hosted by Daewoong Pharmaceutical Indonesia in Jakarta on 29 November 2025.

‍

With the launch of this new product, including Indonesia’s first low-dose 10/5mg Ezetimibe/Rosuvastatin combination, Daewoong plans to strengthen collaboration with major hospitals and healthcare institutions in Indonesia and improve lead improvements in treatment accessibility through its three-strength combination product lineup.

Group photo of the speakers (from right to left): Prof. Won Ho Youn, M.D., Ph.D., a professor of cardiology and a dyslipidemia expert from Korea; Dr. dr. Anwar Santoso, SpJP(K), FIHA, FAsCC, FESC, FACC, Consultant Cardiologist; Prof. Seok-Min Kang, M.D., Ph.D., President of the Korean Society of Cardiology; and dr. Bambang Dwiputra, SpJP(K), FIHA, Cardiologist, during the the panel discussion at the launch of the latest dyslipidemia therapy in the form of a fixed-dose combination of Ezetimibe and Rosuvastatin, hosted by PT Daewoong Pharmaceutical Indonesia in Jakarta on 29 November 2025.

list

- Introduction of Indonesia’s first 10/5mg Ezetimibe/Rosuvastatin combination tablet, expanding treatment options from low- to very-high-risk dyslipidemia patients

- “The lower the LDL-C, the better for cardiovascular prevention”… Dual-mechanism combination therapy aligned with ESC(European Society of Cardiology) guidelines gains attention

- Korean and Indonesian cardiology leaders emphasize early combination therapy over high-dose statin monotherapy for high-risk patients

Privacy Policy

이용약관